Skip to main content

3rd Liquid Biopsies Congress 2021

Novosanis is excited to be present at the Liquid Biopsies congress in Heathrow with a booth & presentation.
The meeting will focus on the latest approaches in biomarker detection, circulation tumour cells, precision medication applications, extracellular vesicles and the growing field of single-cell analysis. Kaye Walton, our Global Business Development and Sales Manager is exited to meet you there!

http://www.global-engage.com/event/liquid-biopsies/

Disclaimer

Novosanis is a wholly owned subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology. The Colli-Pee® family, the heart of the company, allows volumetric and standardized collection of first-void urine. The platform consists of variants capturing a range of urine volumes for different application purposes. Urine collection through the Colli-Pee® device is easy, comfortable, and more accurate than a regular urine cup. First-void urine has shown to improve detection of infectious diseases, including sexually transmitted infections as well as for some cancers applications. The Colli-Pee® device enables immediate mixing of the first-void urine sample with a preservative, improving stability of the urine specimen. Novosanis markets its products worldwide and has a global customer base.